Status:
COMPLETED
IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin
Lead Sponsor:
AstraZeneca
Conditions:
Fredrickson Type IIa & Type IIb Dyslipidaemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the effects on the kidney of rosuvastatin and simvastatin in subjects with Fredrickson Type IIa \& Type IIb Dyslipidaemia
Eligibility Criteria
Inclusion
- Fasting low density lipoprotein level as defined by the protocol.
- Fasting triglyceride level as defined by the protocol.
Exclusion
- The use of lipid lowering drugs or dietary supplements after Visit 1.
- Active arterial disease eg Unstable angina, or recent arterial surgery
- Blood creatine levels above the limits defined in the protocol or +4 proteinuria during dietary lead in period.
- Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
End Date :
April 1 2004
Estimated Enrollment :
442 Patients enrolled
Trial Details
Trial ID
NCT00654446
Start Date
September 1 2002
End Date
April 1 2004
Last Update
March 16 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.